Optiver Holding
CSTL icon

Optiver Holding’s Castle Biosciences CSTL Stock Holding History

Optiver Holding’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.15K Buy
+174
New +$3.88K ﹤0.01% 2053
2025
Q4 		– Sell
-40
Closed -$911 – 2586
2025
Q3 		$911 Buy
+40
New +$813 ﹤0.01% 2508

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Optiver Holding's CSTL Position: Q2 2026 in Review

Optiver Holding opened a new position in Castle Biosciences (CSTL) in Q2 2026: 174 shares worth $4.15K. The stake represents ﹤0.01% of the portfolio and ranks #2053 among its holdings. This is a return to the name: Optiver Holding previously reported a position in CSTL as recently as Q3 2025.

Optiver Holding first reported a position in CSTL in Q3 2025 and has held it in 2 quarters since. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Optiver Holding held 174 shares of Castle Biosciences worth $4.15K as of Q2 2026.
  • Castle Biosciences was a new Optiver Holding position in Q2 2026.
  • Castle Biosciences made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2053 holding.
  • Optiver Holding first reported a position in Castle Biosciences in Q3 2025 and has held it in 2 quarters since.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.